Greg Bosch is CEO of Geistlich Pharma NA, the global leader in regenerative medicine in dental and oral-maxillofacial surgery. Greg was previously President and CEO of PuriCore,  which he joined as CEO in 2004. Prior to joining PuriCore, he held a variety of management and leadership positions with Baxter International. Under his leadership, as Vice President and General Manager of Baxter’s Bio Surgery division, the division experienced growth from  $40 million in 1998 to more than $220 million in 2000. During his 19-year tenure, Greg had international assignments in Austria and Switzerland and was a board member of Baxter AG.  He received the 2006 Life Sciences CEO of the Year award from the Eastern Technology  Council. Greg earned his BA from Duke University and his MBA from DePaul University.